Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
KALV

KALV - KalVista Pharmaceuticals Inc Stock Price, Fair Value and News

$16.95-0.43 (-2.47%)
Market Closed

11/100

KALV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

KALV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KALV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KALV Price Action

Last 7 days

4.4%

Last 30 days

9.3%

Last 90 days

0.2%

Trailing 12 Months

38.4%

KALV RSI Chart

KALV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KALV Valuation

Market Cap

856.8M

Price/Earnings (Trailing)

-4.12

Price/Sales (Trailing)

41.75

EV/EBITDA

-2.48

Price/Free Cashflow

-4.49

KALV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KALV Fundamentals

KALV Revenue

Revenue (TTM)

20.5M

KALV Earnings

Earnings (TTM)

-208.0M

Earnings Growth (Yr)

-48.59%

Earnings Growth (Qtr)

-15.07%

KALV Profitability

EBT Margin

-995.17%

Return on Equity

-1.2K%

Return on Assets

-61.19%

Free Cashflow Yield

-22.27%

KALV Investor Care

Shares Dilution (1Y)

16.81%

Diluted EPS (TTM)

-3.96

KALV Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250010.7M0
202011.8M12.7M00
201918.0M16.1M15.8M14.1M
20183.7M8.4M12.0M16.5M
20171.6M1.5M655.0K1.6M
201602.1M1.9M1.7M
2015916.5K1.8M00
2014318.5K222.0K125.5K29.0K
2013000415.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About KalVista Pharmaceuticals Inc

KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEkalvista.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES118

KalVista Pharmaceuticals Inc Frequently Asked Questions

KALV is the stock ticker symbol of KalVista Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of KalVista Pharmaceuticals Inc is 856.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, KALV's PE ratio (Price to Earnings) is -4.12 and Price to Sales (PS) ratio is 41.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KALV PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, KalVista Pharmaceuticals Inc has provided 0.055 (multiply by 100 for percentage) rate of return.